CFDA Site Inspection Moves Hisun’s Biosimilar Enbrel Forward
This article was originally published in PharmAsia News
Executive Summary
According to the China FDA’s website, Hisun’s monoclonal antibody Anbainuo, a generic version of Pfizer’s Enbrel (etanercept) is now waiting for an on-site inspection from the agency, indicating a potential approval in China within the year.